TEVA Insider Trading

Insider Ownership Percentage: 0.55%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $16,398,934.87

Teva Pharmaceutical Industries Insider Trading History Chart

This chart shows the insider buying and selling history at Teva Pharmaceutical Industries by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Teva Pharmaceutical Industries Share Price & Price History

Current Price: $16.38
Price Change: Price Decrease of -0.085 (-0.52%)
As of 03/14/2025 04:59 PM ET

This chart shows the closing price history over time for TEVA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$16.38Closing price on 03/14/25:

SEC Filings (Institutional Ownership Changes) for Teva Pharmaceutical Industries (NYSE:TEVA)

54.05% of Teva Pharmaceutical Industries stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TEVA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.27Bbought$619MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B$0$1BTotal InflowsTotal Outflows
Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Read More on Teva Pharmaceutical Industries

Today's Range

Now: $16.38
Low: $16.17
High: $16.50

50 Day Range

MA: $18.28
Low: $14.69
High: $22.00

52 Week Range

Now: $16.38
Low: $12.51
High: $22.80

Volume

6,488,903 shs

Average Volume

12,964,806 shs

Market Capitalization

$18.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Who are the company insiders with the largest holdings of Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' top insider investors include:
  1. Roberto Mignone (Director)
  2. Mark Sabag (EVP)
  3. Eliyahu Sharon Kalif (CFO)
  4. Richard D Francis (CEO)
  5. Eric A Hughes (Insider)
  6. Christine Fox (EVP)
  7. Amir Weiss (CAO)
  8. Eric Drape (VP)
  9. Vikki L Conway (Insider)
  10. Eric A Hughes (Insider)
  11. Vikki L Conway (Insider)
Learn More about top insider investors at Teva Pharmaceutical Industries.

Who are the major institutional investors of Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' top institutional investors include:
  1. FMR LLC — 7.24%
  2. Clal Insurance Enterprises Holdings Ltd — 3.44%
  3. Ion Asset Management Ltd. — 3.24%
  4. Menora Mivtachim Holdings LTD. — 2.51%
  5. Lingotto Investment Management LLP — 2.40%
  6. Migdal Insurance & Financial Holdings Ltd. — 2.30%
Learn More about top institutional investors of Teva Pharmaceutical Industries stock.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

During the previous quarter, TEVA stock was sold by these institutional investors:
  1. Arrowstreet Capital Limited Partnership
  2. Slate Path Capital LP
  3. Deutsche Bank AG
  4. Adage Capital Partners GP L.L.C.
  5. Bank of America Corp DE
  6. Parsifal Capital Management LP
  7. Legal & General Group Plc
  8. Sound Shore Management Inc. CT
In the previous year, company insiders that have sold Teva Pharmaceutical Industries company stock include:
  1. Roberto Mignone (Director)
  2. Mark Sabag (EVP)
  3. Eliyahu Sharon Kalif (CFO)
  4. Richard D Francis (CEO)
  5. Eric A Hughes (Insider)
Learn More investors selling Teva Pharmaceutical Industries stock.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

Within the last quarter, TEVA stock was acquired by institutional investors including:
  1. FMR LLC
  2. Duquesne Family Office LLC
  3. Clal Insurance Enterprises Holdings Ltd
  4. Todd Asset Management LLC
  5. Marshall Wace LLP
  6. Northern Trust Corp
  7. Soleus Capital Management L.P.
  8. Janus Henderson Group PLC